Status:
COMPLETED
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
Lead Sponsor:
Eli Lilly and Company
Conditions:
Hidradenitis Suppurativa
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
Eligibility Criteria
Inclusion
- Have a diagnosis of HS for at least 6 months
- Have HS lesions in at least 2 different anatomic areas
- Have inadequate response or intolerance to a 28 day course of oral antibiotics
- Have a total count of abscesses and inflammatory nodules greater than or equal to 4
- Agree to use a topical antiseptic daily
- Agree to stop using topical antibiotics during the study. In certain cases, oral antibiotics will be allowed
Exclusion
- Have more than 20 draining fistulae
- Have received any biologic medication (adalimumab, etc.) for the treatment of HS
- Plan to use oral opioids for HS-related pain during the study
- Uncontrolled depression or suicidal thoughts
Key Trial Info
Start Date :
August 26 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 13 2022
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04493502
Start Date
August 26 2020
End Date
October 13 2022
Last Update
April 28 2023
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas, United States, 72758
2
First OC Dermatology
Fountain Valley, California, United States, 92708
3
Dermatology Research Associates
Los Angeles, California, United States, 90045
4
Skin Care Research, Inc
Hollywood, Florida, United States, 33021